| scholarly article | Q13442814 |
| review article | Q7318358 |
| meta-analysis | Q815382 |
| P2093 | author name string | Michael Steinberg | |
| P433 | issue | 11 | |
| P921 | main subject | dasatinib monohydrate | Q27139135 |
| leukemia | Q29496 | ||
| Philadelphia chromosome | Q1129111 | ||
| dasatinib | Q419940 | ||
| P304 | page(s) | 2289-2308 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia | |
| P478 | volume | 29 |
| Q52681024 | A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies. |
| Q36888962 | A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. |
| Q37870181 | Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients |
| Q37683786 | Acute renal failure under dasatinib therapy |
| Q49188770 | Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review |
| Q92724157 | Albumin Nanovectors in Cancer Therapy and Imaging |
| Q54630535 | Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and |
| Q41935042 | Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors |
| Q35100843 | Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity |
| Q61799199 | Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI |
| Q50427017 | Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells |
| Q37205970 | Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib |
| Q26991890 | Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas |
| Q38313870 | Cancer chemotherapy and cardiac arrhythmias: a review. |
| Q35265868 | Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib |
| Q39189801 | Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells |
| Q43841175 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles |
| Q43122174 | Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. |
| Q34100838 | Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer |
| Q36010168 | Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy |
| Q34708878 | Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. |
| Q40238365 | Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation |
| Q43247067 | Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling |
| Q41885572 | Dasatinib inhibits proinflammatory functions of mature human neutrophils |
| Q36212765 | Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway |
| Q93350819 | Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells |
| Q28468632 | Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity |
| Q47327036 | Development, optimization, and in vitro characterization of dasatinib-loaded PEG functionalized chitosan capped gold nanoparticles using Box-Behnken experimental design |
| Q48193696 | Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2. |
| Q52592617 | Electrophysiologic Toxicity of Chemoradiation. |
| Q44530924 | Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer |
| Q91276909 | Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation |
| Q42013412 | Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics |
| Q47152778 | Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. |
| Q26771790 | Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia |
| Q35555492 | IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma |
| Q34570140 | Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells |
| Q89821434 | Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib |
| Q35178869 | Improved angiostatic activity of dasatinib by modulation with hydrophobic chains |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q64244544 | Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever |
| Q24632515 | Mast cell homeostasis and the JAK-STAT pathway |
| Q47143892 | Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence |
| Q36819466 | Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know |
| Q37787577 | Moving towards dose individualization of tyrosine kinase inhibitors |
| Q45018995 | Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity |
| Q39455649 | Novel agents for the treatment of childhood leukemia: an update |
| Q37188017 | Omics and therapy - a basis for precision medicine |
| Q41524889 | Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case |
| Q37781050 | Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development |
| Q35115436 | Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. |
| Q33722847 | Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. |
| Q38448007 | Renal Toxicities of Targeted Therapies |
| Q37087013 | Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. |
| Q38321432 | Site-specific cleavage of mutant ABL mRNA by DNAzyme is facilitated by peptide nucleic acid binding to RNA substrate |
| Q34182834 | Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data |
| Q35848373 | Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells |
| Q38748552 | Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors |
| Q24596026 | Systematic review of dasatinib in chronic myeloid leukemia |
| Q37896606 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose |
| Q36658033 | The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells |
| Q35076179 | Therapeutic opportunities in noncutaneous melanoma |
| Q45764606 | Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice. |
| Q44004521 | Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma |
| Q42036021 | Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report |
Search more.